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Abstract 
In mammalian development, a complex system comprised of regulatory signals causes 
tissue distinction with unique structures as well as functions. Gene expression controls these 
functions through specific combinations of transcription factors and cofactors that influence cell 
differentiation by both activation and repression of genes.  
Whole genome microarray studies of fibroblasts have identified candidate genes that can 
serve as master regulators of fibroblast identity. A previous study showed that Prrx1 and Snai2 
play important roles in activating expression of fibroblast identity, and Snai2 overexpression in 
hepatoma cells (Fg14) activated expression of fibroblast specific genes. Moreover, Snai2 
overexpression resulted in repression of liver specific genes. This thesis addresses whether 
Twist1 has a similar effect as Snai2. More specifically, the objective of this work is to determine 
how Twist1 transfection of hepatoma cells (Fg14) affects fibroblast specific and hepatoma 
specific genes. 
qPCR analysis revealed that Twist1 was successfully over-expressed in pooled Fg14 
transfectants and individual clones compared to the non-transfected cells. Following these 
experiments, expression of several important genes in hepatic and fibroblast function were 
monitored. Results show that, of the 7 fibroblast specific genes tested, Twist1 overexpression 
activated two genes, Prrx1 and Sema3a, in Fg14 hepatoma cells. However, the remaining 5 
fibroblast genes were not affected.  Twist1 overexpression was found to not affect expression of 
the 10 hepatoma-specific genes tested.   
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Based on these results, unlike results obtained with Snai2 and Prrx1 overexpression 
studies, Twist1appears to have limited potential to reprogram hepatoma cells toward the 
fibroblast phenotype.  
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Chapter 1 
Introduction 
1.1. Gene Regulation in Multicellular Organisms 
 It is vital to have an in-depth comprehension of gene regulation to better understand many 
processes in life organisms. The discovery of the molecular machines that transcribe human genes, 
namely RNA polymerases I, II and III (Pol I, II and III), was a milestone in the research area of 
eukaryotic transcription [1][2][3] and paved the way to understanding the evolution of 
transcriptional regulation in eukaryotes. One of the main challenges in the area is to identify all 
the functional elements in this very complex genome, a subset of which is functional elements[4]. 
 The expression of eukaryotic protein-coding genes occur mostly at the transcription 
initiation level.  Most eukaryotic genes are transcribed by RNA polymerase II and regulated by 
two separate families of DNA sequences which are both cis-acting elements that have recognition 
sites to amplify or suppress transcription. The first family belongs to a promoter that contains a 
core promoter and nearby regulatory elements, whereas the second family belongs to distal 
regulatory elements such as enhancers, silencers, insulators and locus control regions (LCR). An  
illustration  of a typical gene regulatory elements is given in Figure 1[4] and more details are 
presented in the next section. 
 There is much variation in eukaryotes in the quantity of the genes that are transcribed into 
both coding and noncoding RNA species[5]. The human genome has roughly 20,000 protein-
coding genes and even more non protein-coding genes (ncRNA)[6]. Several ncRNAs have been 
shown to take part in gene expression control via modulation of transcriptional or 
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posttranscriptional processes such as fine tuning the levels of target messenger RNAs (mRNAs) 
or selecting chromatin regulators to modify gene expression[7]. 
 
Figure 1.  Schematic of gene regulatory elements. Taken from[4] 
 
Three groups play a role in accurate transcription in eukaryotic cells. These are: general 
transcription factors (GTF) activators which are promoter-specific proteins and coactivators. GTFs 
gather around the core promoter in order to form a transcription preinitiation complex (PIC) which 
leads RNA polymerase II to the transcription initiation site. A complete RNA polymerase II 
elongation complex occurs after several steps including promoter melting, clearance, and 
escape[8]. PIC sitting on the core promoter is only enough for low levels of basic transcription. In 
order to trigger more transcription activity, the second group (activators) come into play.. 
Activators are sequence-specific proteins with separable activation domain[9]. Activators are 
believed to work by increasing PIC formation through the interactions with transcriptional 
targets[10]. The last group that plays a role in correct transcription is coactivators. Coactivators do 
not have sequence-specific DNA binding, they are used by DNA-bound activators[11]. Although 
different in structure, coactivators’ functions are very similar to activators which stimulate PIC 
formation and modify chromatin. 
 3 
 
1.2. The Elements of Transcriptional Regulation 
  There are six different elements that have a significant role in the transcription process as 
can be seen in Figure 1. The first one is the core promoter which is described as the region at the 
starting point of a gene that acts as the docking site for both the PIC assembly and basic 
transcriptional machinery. It dictates position and direction of the transcription[12]. The second 
element is the proximal promoter which is the region that neighbors upstream from the core 
promoter. One important characteristic is to house activators via their binding sites[4]. The core 
promoter and the proximal promoter together make up the promoter part. 
 The remaining four elements are called distal regulatory elements. An interesting question 
to ask can be how these distal regulatory elements function from a distance. According to studies, 
DNA-looping, in which the DNA loops out so that core promoter and distal elements can be 
brought together is responsible[13]. Of them, enhancers increase the transcription capacity and 
perform similar to proximal promoter[14][15]. They regulate the transcription in a spatial or 
temporal-specific way and work regardless of the distance or orientation of the promoter[15]. The 
second distal regulatory element is silencers which have similar structure but act in the opposite 
way of enhancers. They house binding sites for repressors which are negative transcription 
factors[16]. Another element is insulators that block the genes from being affected by the 
neighboring genes. This effectively limits the affecting boundary of the other regulatory 
elements[4]. Two main characteristic of insulators are blocking enhancer-promoter 
communication and averting the spread of suppressive chromatin. Insulators are also called 
boundary elements. The last element in this category is locus control regions (LCRs). As the name 
suggests, they regulate an entire locus or gene cluster[17] with enhancing specific activity being 
the most important characteristic. They function in a similar way to enhancers and silencers.  
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Figure 2.  Distal transcriptional regulatory elements and their functions of each. Taken 
from[4] 
 
1.3. Transcription Factors and Gene Regulation 
 Transcription factors bind to DNA by occupying DNA sequences at control elements (cis-
elements) where they make use of and regulate the transcription apparatus[5]. Transcriptional 
regulation occurs at two different but interconnected levels. The first level includes transcription 
factors and transcription apparatus whereas the second level includes chromatin and its 
regulators[5] (Figure3).  
Transcription factors regulate gene expression through binding to enhancer elements and 
selecting RNA polymerase II and cofactors to target genes[18]. Transcription factors regulate 
transcription by synergistically binding to individual enhancers from core promoters via physical 
contact which involves looping of the DNA that contains enhancers and the core promoters[19]. 
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As mentioned before, transcription factors bind to cofactors which are protein complexes 
that leads to activation (termed coactivators) and repression (termed corepressors). By making use 
of coactivators, transcription factors are believed to assist transcription initiation. After the 
transcription is initiated by RNA polymerase II, only a short distance of 20 to 50 bp is transcribed 
due to pause control factors.  At the next step, these paused polymerases transition to elongation 
with the help of positive transcription elongation factor b (P-TEFb) which can be a component of 
super elongation complex (SEC).  
The second level of transcriptional regulation involves chromatin (Figure 3, right). The 
main unit of chromatin is the nucleosome that is governed by protein complexes capable of 
mobilizing and altering its histone components. Mobilizing nucleosomes with the help of ATP-
dependent chromatin complexes help them access to the transcription apparatus A[20]. There are 
also a variety of histone-modifying enzymes that modify nucleosomes of each active gene[21]. 
The alteration helps create a dynamic environment for chromatin modification as RNA polymerase 
is used in the process of initiation and elongation of the RNA species. There are several types of 
repressed chromatin[22] which are embedded: one type contains nucleosome alterations by the 
Polycomb complex which are silent but ready for activation at later stages of development[23] and 
the other type is completely silenced[24]. 
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Figure 3.  Schematic of transcriptional regulation. Taken from[5] 
 
1.4. Liver Development and Hepatocellular Carcinoma 
 Being the largest gland in mammals, the liver has endocrine functions such as insulin-like 
growth factors, angiotensinogen, and thrombopoietin secretion and exocrine properties like bile 
secretion[25]. It is the main player in a variety of bodily functions such as glycogen storage, drug 
detoxification, metabolism control, overseeing cholesterol synthesis and transport and plasma 
protein secretion. Liver diseases such as hepatic fibrosis, cirrhosis and hepatitis tend to have a high 
morbidity rate and are reported to be the fourth leading cause of death in the United States among 
middle-aged people[25]. Comprising 2-5% of the whole body mass and being mostly made from 
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hepatocytes, this organ is responsible for many functions, including purification of proteins and 
production of growth factors, signaling molecules and hormones.  
 Being mostly comprised of hepatocytes, the liver has a very complicated tissue 
architecture. The liver lobule can be thought of the main building block of the liver. Plates of 
hepatocytes are separated by sinusoidal capillaries are arranged around central veins. Hepatocytes 
make up 78% of the liver and are responsible for protein and bile secretion, detoxification, 
cholesterol, urea and glucose regulation, acute phase response and blood clotting[26]. There are 
other types of cells in the liver.   Cholangiocytes (bile duct cells) make up 3% of the liver and form 
bile ducts, control bile flow and pH and secrete water and bicarbonate as necessary.  Endothelial 
cells line the lumen of blood vessels. Sinusoidal cells which are responsible for transferring of 
molecules between serum and hepatocytes, scavenging of waste, secretion of cytokine and antigen 
presentation. Pit cells are in charge of cytotoxic activity, while Kupffer cells scavenge foreign 
material and secrete cytokines.  Finally,  hepatic stellate cells are in charge of maintaining 
extracellular matrix, vitamin A synthesis, and retinoid deposition. 
 Developing cardiac mesoderm has an indispensable role during the hepatic cell fate phase 
based on the studies done on mouse and chick embryos[27][28]. Fibroblast growth factor (FGF) 
family is responsible for these inductive signals as FGF1 and FGF2 are capable of substituting 
cardiac tissue at the Albumin kickoff which is known to be characteristic to hepatic cell fate[29]. 
FGF-induced (including Fgf1, Fgf2, Fg8, and Fg10 which are believed to have overlapping 
functionality[30]) hepatic gene expression is regulated via mitogen-activated protein kinase 
(MAPK) pathway in the cardiac mesoderm during the hepatogenesis knockoff phase[31]. FGF 
signaling necessity is conserved throughout t evolution, as Xenopus, chick and Zebrafish embryos 
exhibit the same requirements[32].  
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 Cells going through a hepatocyte cell fate acquire a certain gene expression and 
physiological profile during the embryonic and postnatal phases[33]. There is a complex network 
of transcription factors in the hepatocyte gene expression regulation. The main players in this 
network are HNF1a, HNF1β, FoxA2, HNF4a, HNF6, and LRH-1 [Nr5a2] working by occupying 
each other’s promoters and thus form the regulatory circuity[34]. HNF1b, FoxA2, and HNF6 are 
involved in controlling the hepatic gene expression kickoff during the specification and liver bud 
formation[25]. HNF1a does not seem to have a big impact during embryogenesis which is thought 
to be the HNF1β occupying the HNF1 binding sites initially but in the adulthood phase HNF1β 
occupied promoter sequences were observed to be bound by HNF1a[35]. HNF4a does not seem to 
affect hepatic speciation although subsequent differentiation is blocked[36]. In fetal hepatic 
progenitors, the lack of HNF4a has a serious drawback[34] and preserving character in mature 
ones are reported in the literature[37]. 
 Even though there are many diseases associated with liver malignancy hepatocellular 
carcinoma (HCC) is the most common one and is the ninth leading cause of cancer deaths in the 
United States[38]. HCC is more prevalent in males than females by a ratio of 2.4 to 1 with a higher 
strike rate for people with Eastern and Southern Asia, Middle and Western Africa, Melanesia and 
Micronesia backgrounds[39].  Chronic liver disease, cirrhosis, viral hepatitis, and excessive 
alcohol consumption are the leading risk factors of HCC[38].  Chronic medical conditions, namely 
obesity (which is believed to increase the risk by 1.5 to 4 times) and diabetes mellitus (due to the 
liver’s important role on glucose metabolism), also increase the risk of HCC.  Treatment of HCC 
patients is rather limited since the diagnosis are often done on patients with advanced HCC which 
have gone through some liver damage already[38].  Among the treatments surgical techniques 
such as resection[40], liver transplantation[41] as well as nonsurgical techniques such as 
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transarterial chemoembolization[42], transartetial radiation[43], percutaneous local ablation[44] 
and microwave ablation[45] exist. 
Many of the known processes driving liver function have been identified through the study 
of hepatoma cells which makes them favorable as a model for liver function. For example, several 
key liver-specific transcriptional regulators have been identified using cultured liver-derived 
cells[46]. More recently, hepatoma x fibroblast cell hybrids were used to identify candidate genes 
possibly involved in driving both hepatic and fibroblast cell function using whole genome 
approach.  Of the genes identified as highly fibroblast-specific, two genes, Snai2 and Prrx1, were 
shown to be able to reprogram cells hybrids to a fibroblast phenotype. Furthermore repression of 
either of these genes in a fibroblast cell line resulted in dramatic reprograming of cells into a variety 
of cell lineages, including chondrocyte and adipocyte cell phenotypes. Overexpression of these 
genes in a hepatoma cell line resulted in repression of hepatoma genes and activation of fibroblast 
genes.  
1.5. Fibroblast as a Cell Model System 
 Within the body’s connective tissues, fibroblasts are the most common cell type. Their 
main role is to secrete the components of the extracellular matrix (ECM)[47]. Fibroblasts are a 
family of very heterogeneous multifunctional cells which have an important role in development 
processes[48]. They are also instrumental in repairing tissue damage from inflammation and injury 
since they can produce different types of paracrine immune modulators[49]. Fibroblasts are also 
thought be involved in tumor development and progression as cancer and chronic inflammation 
exhibit some analogies[50]. 
 Fibroblasts are found in most of the tissues and organs in the body and is associated with 
extracellular matrix (ECM) molecules[51]. Fibroblasts derive embryonically from mesenchymal 
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origin with a variety of phenotypic characteristics[52]. More recent findings suggest that the source 
of fibroblasts after injury or disease can come from epithelial-mesenchymal transition (EMT) and 
mesenchymal stem cells which are derived from bone marrow and tissue[53].  
 One of the most important functions of fibroblasts is the generation and control of ECM of 
the tissue or organ. Fibroblasts do this function by synthesizing and secreting collagens, 
proteoglycans, fibronectin, tenascin, laminin and fibronectin. They are very active cells and each 
cell is thought to synthesize 3.5 million procollagen molecules per day[54]. Fibroblasts also 
generate matrix metalloproteinases, their inhibitors, and tissue inhibitors of metalloproteinase that 
regulate extracellular degradation. Another important function of fibroblasts is regulation of tissue 
interstitial fluid volume as well as pressure through interaction of β1 integrin receptors[55]. The 
last important function of fibroblasts is the involvement in wound healing and repair which 
includes clot formation and platelet degranulation followed by releasing mediators to attract 
relevant cells to the wound area[56]. It replaces the matrix with a more mature ECM and 
subsequently heals the wounded site.  
1.6. Twist-related Protein 1 (Twist1) 
 Twist1 was first identified in Drosophila as an indispensable gene for mesoderm formation 
and differentiation into different distinct tissue types as well as dorsal-ventral patterning in the 
early embryo development phase[57]–[60]. The name was given since the Drosophila embryos 
lacking Twist1 gene died at the end of embryogenesis looking “twisted”[60]. The Twist1 gene 
encodes a transcription factor that is comprised of a basic helix-loop-helix (bHLH) domain as well 
as an amino-acid motif[61]–[63]. The important role of Twist1 in the development of mesoderm 
has been established. For example, Twist1 gene mutations in human cause Saethre-Chotzen 
syndrome which is an autosomal dominant inheritance disease[64]. Similar effects were observed 
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in gene-ablation studies involving Twist1 null mice[65]. More recently, a crucial role Twist1 plays 
in cancer metastasis has emerged in the literature[66]–[68]. 
 Belonging to the bHLH family which is characterized by the formation of a domain 
consisting basic amino acids sitting next to two amphipathic α-helices that are separated by an 
inter-helical loop[61]. The α-helices moderate the interaction with another bHLH factor and cause 
the production of  a dimer that binds to Nde1 E-box which has an indispensable role for a variety 
types of organogenesis[63]. There are three subfamilies within bHLH family. Class A proteins are 
omnipresent among the mammalians. Class B proteins are specific to tissue expression and form 
dimers with class A molecules in order to bind to E-boxes. The final class C subfamily do not form 
dimers with other classes. Twist1 belongs to the family of class B[69]. 
 
Figure 4.  Location of Twist1 gene in human. Taken from[70] 
 
 Human Twist1 gene has two exons and one intron and is mapped to 7p21.2[71] as   shown 
in Figure 4. The first exon contains an ATG site which is followed by 202 amino-acid residues 
that are in turn followed by an untranslated portion (45-bp) in exon 1, 536-bp intron and another 
untranslated portion in exon 2[57]. Human Twist1 molecular weight is approximately 21 kDa, and 
has a theoretical isoelectric point of 9.6. This protein has more polar amino-acid residues near the 
NH2 ends whereas more nonpolar residues at the COOH ends. Hence, NH2 terminus is more 
hydrophilic. 
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Human Twist1 protein and mouse Twist1 protein are 96% identical with the bHLH domain 
between residue109 to residue163 has exactly the same homology[72]. Molecular structure of human 
Twist1 protein is shown Figure 5. Moreover, bHLH domains of Twist1 is mostly conserved among 
many species such as human, mouse, frog, Drosophila, leech and Caenorhabditis elegans. 109Q – 
T121 region of human Twist1 protein is the main region in charge of binding to DNA. Furthermore, 
Loop-Helix II region also plays a role in the DNA binding process. Not only does Twist1 form 
dimer in order to bind to DNA, it also interacts with MyoD which is responsible for muscle 
differentiation. Hence, this interaction leads to suppression of muscle differentiation[73].  
 
Figure 5.  Molecular structure of human Twist1 protein. Taken from[57] 
 
Twist box (also called WR motif) which is found between 20 and 55 amino acids from 
COOH-terminal to bHLH area is protected among vertebrates. This region has 100% homology 
among human (corresponding to between residue180 and residue202), mouse and Xenopus[57]. On 
the contrary, a more historic species such as C. elegans does not contain a WR dipeptide. This WR 
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domain is necessary for the transactivation of Twist1 and any genetic mutation in this area results 
in Saethre-Chotzen syndrome for humans[74].  
Aside from Twist1, there is also Twist2 protein. The Twist2 protein in humans has 160 
amino-acid residues and it has only 68% identical homology-wise. However, the amino-acid 
sequences in bHLH and Twist box domains are essentially identical and it is the reason for their 
mutually redundant functions[57]. 
Being a major player in organogenesis, Twist1 is mostly expressed in tissues derived from 
mesoderm. In Drosophilia, it has been shown that cellular blastoderm stage is the first phase 
Twist1 is detected[75]. In the early gastrulation era, Twist1 expression is observed to be high in 
the mesodermal layer of the embryos. Late gastrulation phase comes and Twist1 can be observed 
in the cells of germ band mesodermal layer as well as anterior midgut primordium. In the later 
stages, Twist1 expression weakens but can still be seen within the mesodermal layer of 
somatopleura and splanchnopleura. After birth happens, it can be observed in adult mesenchymal 
cells such as muscle stem cells[76][77]. It is worth mentioning that at all developmental stages, 
Twist1 is localized in the nuclei since it is a nuclear protein. 
As another important model, Twist1 is first observed at embryonic day 7.5 during mouse 
embryogenesis in the anterior-lateral mesoderm underneath the head folds, inside the primitive 
streak epiblast as well as in scattered cells in the amniotic cavity[77][78]. Afterwards, Twist1 is 
observed sequentially in the metameric segments, the neural crest derived head mesenchyme, the 
first aortic arches, the lateral mesoderm, the second, third and fourth branchial arches, the anterior 
limb buds, and finally, the posterior limb buds[79]. Twist1 is likely to be expressed initially along 
a dorsoventral gradient pattern until the headfold phase, followed by expression along the rostro-
caudal axis of the embryos[57].  
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Unfortunately, dominant Twist1 expression areas during embryo development stages for 
humans are not as developed as Drosophilia and mouse, although there have been reports in the 
literature. Twist1 expression was strongly observed in the placenta. More specifically, in the fetal 
region of the placenta which is unsurprisingly comes from the mesoderm[71]. Less strong 
expression levels were observed in the adult heart and skeletal muscle. Even weaker signals were 
seen in the kidney and pancreas whereas brain cells which are derived from ectoderm and lung 
and liver cells which are derived from endoderm did not express any Twist1 signal. Considering 
cell lines derived from human, WI-38 cells (fetal fibroblasts from lung), human peritoneal 
mesothelial cells and endometrial fibroblasts as well as mesenchymal stem cells derived from bone 
marrow showed Twist1 signals[80]. To summarize, Twist1, an indispensable gene for 
organogenesis, is mostly expressed in the mesoderm-derived cells. After birth, it is mostly 
expressed in adult stem cells. 
Twist1 is a vital regulator of many biological processes. Required for the proper 
development of mesenchyme derivatives, Twist1 executes a set of downstream target genes[81]. 
However, the exact molecular mechanism of Twist1’s role on mesenchymal tissue formation is 
not developed[69]. 
One signaling Twist1 is involved is Fibroblast Growth Factor (FGF) signaling 
pathway[82]. In Drosophilia Twist1 activates the expression of DFR1 and in C. elegans eg1-
15[69]. As mentioned before, mutations in Twist1 causes Saethre-Chotzen syndrome which is 
believed to be due to the necessity of Twist1 for FGF signaling during morphogenesis[83]. 
Apart from FGF signaling, Twist1 is also involved in Bone morphogenetic protein (BMP) 
and probably Transforming Growth Factor-β (TGF-β) signaling[84]. As opposed to other bHLH 
proteins, Twist1 has the ability to build functional homodimers (T/T) as well as heterodimers with 
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E12 (T/E). Homodimers and heterodimers have different actions and influence different gene sets’ 
expression. It is possible to pinpoint the ratio between these dimers by checking relative levels of 
Twist1 and helix-loop-helix Id proteins as Twist1 tends to form heterodimers when Id proteins are 
absent and homodimers when present[84]. Id proteins are a different class of HLH and compete 
with Twist1 by forming dimers with E12 and inhibiting heterodimer formation by Twist1s[85]. In 
light of this knowledge, in the areas where Twist1 and Id1 are expressed together such as fronts of 
cranial structures, genes regulated by T/T dimers are expressed. On the flip side, T/E regulated 
genes are expressed in mid-sutures and it has been shown to suppress BMP signaling[82][86]. As 
BMP signaling activates Id expression, it leads to more homodimer (T/T) formation. This makes 
up a positive feedback loop that is believed to cause the early closure of the sutures[57]. Similar 
effect takes place in the limb bud for the case of FGF signaling[87]. Twist1 is also found to be 
indispensable for Bmp4 expression in the apical ectoderm[87]. 
An opposite feedback loop, namely negative feedback, happens in Tumor necrosis factor 
(TNFα) which activates both proapoptotic and antiapoptotic pathways. In order to prevent 
apoptosis, TNFα activated NF-κB upregulates Twist1 as well as Twist2. In response to this, Twist1 
and Twist2 reacts with a subunit of NF-κB to inhibit cytokine genes expression[57]. This negative 
feedback loop is thought to have a role in impeding overactivation of cytokine expression[88]. 
Another very important role Twist1 plays besides the role in organogenesis is the 
expression of in aggressive tumors in a variety of cancer types such as breast cancer[66], 
hepatocellular carcinoma[89], prostate cancer[90], gastric cancer[91], esophageal squamous cell 
carcinoma[92], bladder cancer[93] and pancreatic cancer[94]. Twist1 has a presence in cancer 
initiation, progression as well as metastasis[57]. Amino acid sequences of well characterized 
species are shown in Figure 6. 
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Figure 6.  Amino acid sequences among human (H), mouse (M), xenopus (X), Drosophilia 
(D), leech (L) and C. Elegans (C). Taken from[57] 
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 Most well-known effects of Twist1 in cancer is the promotion of cancer cell (epithelial-
mesenchymal transition) EMT and metastasis. Metastasis has many steps including EMT, local 
invasion, intravasation, transportation, extravasation, proliferation at another site and production 
of overt metastatic lesions[95].  Just as it does for development, Twist1 exhibits a similar behavior 
by supporting the cells to undergo EMT and move to form secondary tumor sites[96].  
 Although Twist1 plays an important role in many types of cancers, the way it expresses, 
functions and the molecular mechanisms affected in this process vary for each type of cancer. Due 
to the topic of the thesis, I will cover only the hepatocellular carcinoma (HCC). HCC is a metastatic 
tumor characterized by  rapid growth[57]. It has been shown that Twist1 overexpression has a 
positive correlation with HCC metastasis and a negative correlation with E-cadherin 
expression[89]. The demonstration of higher levels of Twist1 and lower levels of E-cadherin 
corresponding to higher metastatic capability implies that Twist1 inhibits E-cadherin expression 
and activates EMT alterations[89]. Upregulation of vascular endothelial growth factor (VEGF) 
and N-cadherin by Twist1 in HCC points to Twist1’s role in HCC angiogenesis[97]. Another study 
demonstrated the increased mobility effect of overexpression of Twist1 on HCC cells[98]. In a 
study[99] involving Twist1 with two other major EMT regulators (Snail and Slug) the synergistic 
effect of Twist1 and Snail in enhancing HCC metastasis was demonstrated. Co-expression of Snail 
and Twist1 decreased E-cadherin and deteriorated prognosis significantly compared to Twist1 
expression alone whereas Slug expression was not significant. Further verification comes from a 
study demonstrating Twist1’s effect on increased motility, invasiveness via inhibiting E-cadherin 
expression and upregulation of N-cadherin[100]. 
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1.7. Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT 
 Epithelial tissue is comprised of tightly-packed epithelial cells and is useful to protect the 
body from outside hazards as this tight packing of cells provide the required structural robustness 
due to strong cell-cell and cell-matrix interactions[101]. As opposed to epithelial tissue 
mesenchymal tissue is a loose connective tissue that exists in early embryo. Composed of 
fibroblast-like shaped cells, mesenchymal cells are highly mobile thanks to their loose 
interactions[102]. Being undifferentiated, mesenchymal cells have stem cell properties. 
In the beginning phase of an organism’s development, there is only a single cell which is 
the fertilized egg. As time passes, the multiplied cells from the egg have to differentiate into three 
separate tissue types which are endoderm, ectoderm and mesoderm. The differentiation process 
was once believed to end after a certain time passes[101] but more recent evidence showed 
differentiation continues in response to physical damage and stress[103][104]. Epithelial-
mesenchymal transition (EMT) is a biological process of epithelial cells gaining mesenchymal 
properties via physical and biochemical changes, and is the mechanism for cellular diversity. As a 
result of this process, epithelial cells lose their rigid architecture and become mobile, apoptosis 
resistant cells just like mesenchymal cells. Figure 7 shows the process of EMT[105]. After the 
transition, these cells move around the body to perform tasks such as tissue reconstruction and 
repair[106]. After migrating to the necessary part of the body, these cells undergo a reverse 
transition called mesenchymal-epithelial transition (MET) to become rigid, immobile cells once 
again[107].  
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Figure 7.  Functional transition from epithelial to mesenchymal phenotype. Taken 
from[105] 
 
 Besides being a key player in for embryonic development, EMT also plays an important 
role in tumorigenesis since it promotes invasive and metastatic properties of epithelial cancer cells 
according to animal studies conducted[108]. Some signaling pathways involved in EMT during 
embryonic development are present in EMT during carcinogenesis[101]. It was suggested that 
these epithelial cells from the primary tumors become motile through the process of EMT and 
move away from the primary tumor area and cause secondary tumors at distant places where they 
have metastasized.  They again become rigid and immotile once again through the process of 
MET[106]. This behavior has been observed for breast, ovarian, colon, and esophageal 
cancer[109].  
 It is important to state there is not only one type of EMT and each one occurs for a specific 
type of requirement. Type I EMT is linked to implantation, embryo formation, and organ 
development and thus pivotal in cell type differentiation. It is possible to go back to form epithelial 
cells through the process of MET. Type II EMT, on the other hand, occurs in reaction to an 
inflammation and stops once the inflammation is reduced. Hence, type II EMT occurs during tissue 
repair and damage healing. Type III EMT is found in solid tumors and makes the epithelial cells 
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invasive, leading to metastasis. A schematic showing all three types of EMT is illustrated in Figure 
8[105]. 
 
 
Figure 8.  Three different types of EMT. Taken from[105] 
 
  During EMT, gene expression levels are altered as down-regulation of epithelial markers 
such as E-cadherin and up-regulation of mesenchymal markers such as vimentin and N-cadherin 
occurs[104]. The most important marker for EMT is the E-cadherin which plays a significant role 
in cell-cell adhesion[107]. Since E-cadherin is important for epithelial cells to be immotile, 
reduction of E-cadherin levels leads to increase in invasiveness and change of adenoma to 
carcinoma. Hence, expression of E-cadherin is inversely correlated with tumor grade and 
stage[110][111]. E-cadherin levels are regulated both at the genomic and transcriptional level. It 
is possible to reduce activation of E-cadherin gene CDH1 by mutations as well as loss of CDH1 
heterozygosity and hyper-methylation of CDH1 promoter[107]. Activation of EMT-inducing 
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pathways is possible through the use of growth factors such as fibroblast growth factor, epidermal 
growth factor, hepatocyte growth factor and transforming growth factor (TGF-β).  The last factor 
is instrumental in many processes in the body including regulating growth, as well as 
differentiation and migration of cells during cancer progression, and metastasis[112]. 
 The crucial players of EMT pathways are also E-cadherin repressors. One of them is Snail 
which is a zinc finger DNA binding protein present in normal growth as well as tumorigenesis and 
has been shown to be an important mediator of EMT in human and mouse invasive carcinoma 
cells[112]. Another important EMT inducer is Twist, a helix-loop-helix transcription factor. Twist 
inhibits E-cadherin via binding to E box motifs which are also directed by Snail and overexpression 
of both inducers has been shown to be linked to loss of E-cadherin as well as increase in N-cadherin 
in human gastric cancer[113]. Many EMT-inducing transcription factors act synergistically. For 
example, in human cells Twist1 activates Snail2 by directly binding to its promoter area and these 
two transcription factors are believed to be conserved through evolution and play an important role 
during embryogenesis and tumor metastasis[114].  
 Other studies on EMT focused on the effect of epigenetic alterations on up-regulation of 
epithelial genes and down-regulation of mesenchymal genes during EMT[112]. TGF-β supports 
the epigenetic control of EMT by inducing a DNA methyltransferase, namely DNMT1. It also 
reduces the heterochromatic marker, di-methylation of Lys9, and increases euchromatin 
marker[108]. Snail expression, in various types of carcinoma, is related to the E-cadherin promoter 
hyper-methylation by binding to the promoter region. Afterwards, Snail uses a complex including 
histone deacetyltransferases 1 and 2. Using this complex results in histone H3/H4 acetylation and 
an increase in histone H3 methylation that in turn induces heterochromatic structure and restrains 
E-cadherin expression[112].  
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 As an environmental factor hypoxia, defined as pressure of O2 levels being less than 10 
mm Hg, is correlated with normal development and tumor progression[101]. Low oxygen 
environment up-regulates hypoxia inducible factor (HIF-1) which interferes with the hypoxic 
response by producing a transcription factor that activates transcription of target genes[104]. 
Hypoxia conditions up-regulate Snail and Twist, possibly through TGF-β stimulation[108] by 
inducing Snail and Twist expression which reduces the expression of E-cadherin. 
1.8. Project Overview and Goals of the Study 
 The most important roles Twist1 plays are involvement in organogenesis and the 
expression of aggressive tumors in a variety of cancer types including hepatocellular carcinoma. 
Besides Twist1, Snai2 is another EMT regulator according to previous studies[99]. Previous 
studies showed that Snai2 overexpression in hepatoma cells (Fg14) activated expression of 
fibroblast specific genes[115]. Moreover, Snai2 overexpression resulted in repression of liver 
specific genes. This thesis addresses whether Twist1 has a similar effect as Snai2. More 
specifically, the objective of this work is to determine how Twist1 transfection of hepatoma cells 
(Fg14) affects fibroblast specific and hepatoma specific genes.    
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Chapter 2 
Materials and Methods 
2.1. Cell Culture 
 All cells were stored in a medium that contains 1:1 Ham’s F12/Dulbecco’s modified 
Eagle’s medium (FDV) which consists of 10% fetal bovine serum (FBS) (GIBCO BRL) and 5 
µg/100 ml penicillin-streptomycin (GIBCO) at a temperature of 37° C with 5% humidity CO2 
water-jacketed incubator. FG14 cells were derived from the parental cell line H4IIEC3 cells, 
isolated from a rat tumor by Weiss and colleagues. RAT2 cells are a thymidine kinase negative 
variant of the rat fibroblast cell line RAT1 and were obtained from American Tissue Type 
Collection (ATCC). 
Commercially available Lipofectame kit from Invitrogen was used to transfect the cells 
with candidate genes. Briefly, DNA was mixed with a liposome reagent, trapping the DNA inside 
the liposomes and allowing liposomes to fuse with cell membranes to release the DNA into the 
cells. Expression vectors containing candidate gene TWIST1 was purchased from Origene, Inc. 
Six-well cell culture plates were used for the transfection process of candidate genes. Specifically, 
0.5 ml of FDV media without penicillin and streptomycin (Pen/Strep) was added to a micro-
centrifuge tube., DNA (1 µg/µl) was added, mixed then and 5 µl Lipofectamine Plus reagent was 
added to the  mixtures   and mixed gently for five minutes at room temperature. Finally, 5 µl of 
Lipofectamine LTX reagent was added to the mixture and was mixed gently by pipetting and 
incubated for half an hour at room temperature. 
Cells to be transfected were introduced in a 6-well format the day before transfection. The 
transfection mixture that was prepared in the microfuge tubes before was added in the wells of the 
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plates and incubated at 37°C with 5% CO2 for 6 to 8 hours while rocked. Afterwards, medium was 
substituted with FDV containing 10% fetal bovine serum, penicillin and streptomycin and 
incubated for 2 days at 37°C in 5% CO2 environment. Cells were split into various dilutions (1:20, 
1:10 and 1:5 dilutions) in complete medium plus 500 µg /ml G418 and was incubated for 2 to 3 
weeks. After this process, G418 resistant clones were either pooled (10 to 50 clones per pool) or 
picked individually then expanded into larger plates until the cells could be lysed and ready for 
RNA extraction.  
To determine the transfection efficiency, cells were also transfected with a Green 
Fluorescent Protein (GFP) expression plasmid.  Based on GFP positive cells after 48 hours, we 
estimated between 4 and 6% transfection was achieved   Furthermore, a DNA free control plate 
was used a negative control to make sure no G418–resistant cells were present in the cell line being 
transfected. 
2.2. RNA Isolation 
 RNA extraction from confluent cell lines was performed using an RNeasy Mini Kit from 
Qiagen, with a DNase-I step modification. Briefly, the medium was removed, and the denaturing 
reagent guanidine isothiocyanate (GITC) and β- mercaptoethanol (RLT buffer) were used to lyse 
the cells. Following this procedure, lysed cells were placed in a collection tube for homogenization 
by centrifugation through a QiaShreddr (Qiagen) mini-column. One volume of ethanol was added 
followed by application of an RNeasy column in a collection tube. RW1 buffer was used to wash 
the resin filter and digested with DNase I for 15 min at room temperature. The filter was washed 
with RW1 again first and RPE buffer second followed by quick centrifugation after each treatment. 
RNA was then eluted from resin filter by addition of 40 µl to the column followed by centrifugation 
at 10,000 x g for 1 minute. Extracted RNA samples were transferred to microfuge tubes and stored 
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at -70° C. Nano-drop spectroscopy at 260 and 280 nm was used to determine concentration and 
purity of the purified RNA. 
2.3. cDNA Synthesis 
 A mature, fully spliced, messenger RNA was used to acquire complementary DNA with 
the help of reverse transcriptase enzyme. In this procedure, Poly-T oligonucleotides anneal to poly-
A tails of the RNA and addition of it creates the required complimentary DNA strand which was 
generated by first digesting the RNA strand using Ribonuclease H. Afterwards, complementary 
strand synthesis yields the double stranded DNA. 
To produce cDNA from previously purified RNA, MasterAmp High Fidelity RT-PCR kit from 
Applied Biosystems was used. Reaction mixtures contained 10X RT Buffer, 25uM dNTP Mix, 
10uM RT Random Primers, MultiScribe, sterile nuclease free water and 1 µg RNA in a final 20 
µl volume. The RNA mixture was incubated at 37° C for 30 minutes. The settings in the Bio-rad 
Thermal Cycler used to synthesize cDNA are: 25°C for 10 min, followed by 37°C for 2 hours, 
85°C for 5 min, then 4°C until final products are transferred to a microfuge tube and stored at -
20°C. Afterwards, the stored cDNA tubes were diluted to the previously determined concentrations 
to be used for quantitative PCR.  
2.4. Primer Design 
Primer design was done using software provided by NCBI which is programmed to 
optimize and identify primer pairs that hybridize to single gene targets at appropriate temperatures 
(between 55 and 65°C in our case) and produce short amplicons when using qPCR. The suitable 
primers were purchased from Integrated DNA Technologies Inc. Three primers sets were designed 
for each gene to be tested. The best performing primer set (producing optimal amplification with 
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lowest background signal for both cells of interest) namely the parental hepatoma cells and 
fibroblasts cells were used for subsequent experiments. Genes whose expression was known to be 
significant in hepatic and fibroblast function based on the literature was monitored using qPCR. 
Primer pairs in this study and their predicted melting and annealing temperatures are given in the 
Tables 1 and 2. 
Table 1. Primers used in the quantitative Polymerase Chain Reaction (qPCR), primer sequences, 
melting temperature and annealing temperature of primers for the parental hepatoma cells. 
Primer Primer Sequence Melting 
Temperature 
Annealing 
Temperature 
Hnf1 F-5' CCATTCTGAAAGAGCTGGAGAAC3' 
R-5' AGGTACGACTTGACCATCTTTGC3' 
57.1 
55.6 
60 
Hnf4 F-5' TGGCAGAACTCCATCCGTCATTC3' 
R-5' AACTGGATCTGCTCGATCATCTG3' 
56.6 
56.5 
60 
Hnf6 F-5’ CAGTGGCTCTAAGCACAGTAA 3’ 
R-5’ CAGTGTGGTGGAACAGATAAGA 3’ 
54.5 
54.3 
60 
Serpina1   F-5’ CCTATACCGGGAGCTGGTCCAT 3’ 
R-5’ TTGCGAGTGTCACCCTTGCT 3’ 
60.3 
59.5 
64 
Alb F- 5’ CATCCTGAACCGTCTGTGTG 3’ 
R-5’ TTTCCACCAAAGACCCACTA 3 
55.7 
55.8 
60 
rKng1(1) F- 5’ AACACAATTGCCGCCTTCTCACAG 
3’ 
R-5’ GTGCAATGGAATGACCAAGTGCCT 
3’ 
60.2 
60.2 
64 
rFgb1 (4) F-5’ AAGGAGACAAGGTGAAGGCACACT 
3’ 
R-5’ AAGAACATGCCGTTGTGGATGCTC 
3’ 
60.3 
59.9 
64 
rPck1 (2) F- 5’ CGCTATGCGGCCCTTCTTT 3’ 
R-5’ CGTGAAAGATCTTGGGCAACT 3’ 
58.3 
57.5 
60 
Gapdh F-5’ TGATTCTACCCACGGCAAGTT 3’ 
R-5’ TGATGGGTTTCCCATTGATGA 3’ 
56.5 
54.2 
60 
rCreg1 (3)   F-5’ CATCAGACACCCTGAGATGAAA 3’ 
R-5’ GGTCCACCAAAGTAGTCCAAA 3’ 
54.4 
54.8 
60 
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Table 2. Primers used in the quantitative Polymerase Chain Reaction (qPCR), primer sequences, 
melting temperature and annealing temperature of primers for the parental fibroblast cells. 
Primer Primer Sequence Melting 
Temperature 
Annealing 
Temperature 
Prrx1 F-5' GAACCGAAGCTGGGAGAAA 3' 
R-5' AGGAGAGAGAGAGAGAGAGAGA 3' 
54.9 
54.9 
60 
Snai2 F-5' CTGGATACTCCTCATCTTTGGG 3' 
R-5' CTCTTCGTCACTAATGGGACTT 3' 
54.5 
54.1 
60 
C-Fos F-5' GCTGGTGCATTACAGAGAGAA 3' 
R-5' GTGTGTTTCACGCACAGATAAG 3' 
54.8 
54.3 
60 
Twist F-5' TCGCTGAACGAGGCATTT 3' 
R-5' GCCAGTTTGAGGGTCTGAAT 3' 
54.8 
55.1 
60 
Shox2 F-5' CTGAAGGATCGCAAAGAGGATG 3' 
R-5' CGTTGAGTTGTTCCAGGGTAAA 3' 
55.6 
55.2 
60 
Sppl F-5' CAGCCAAGGACCAACTACAA 3' 
R-5' TGCCAACTCAGCCACTT 3' 
55.0 
54.8 
60 
Bmp3 F-5' CTAGAGGCTAGAGGGAGAACTT 3' 
R-5' GACAGAGAGACAGAGACAGAGA 3' 
54.9 
54.8 
60 
Col1a1 F-5' ACTGGTACATCAGCCCAAAC 3' 
R-5' GGAACCTTCGCTTCCATACTC 3' 
55.0 
55.3 
60 
Sema3a F-5' GGGACGAGACTTTGCTATCTTC 3' 
R-5' GATGGGCACTGATGAATCTAGG 3' 
55.1 
55.1 
60 
 
2.5. Quantitative-Polymerase Chain Reaction (qPCR) 
All the cDNA samples were diluted to a concentration of 5 ng/µl for all the samples. A 
final volume of 20 µl of reaction mixture contained 2 µl of cDNA template at a concentration of 5 
ng/µl, 6.75 µl of sterile nuclease free water, 10 µl of Fast SYBR® Green Master Mix purchased 
from Applied Biosystem and 1.25 µl of gene specific primer at a 0.5 µM concentration (IDTDNA). 
To quantify the expression of mRNA level, Applied Biosystem thermocycler was used. The first 
step was done at 95° C for 3 sec which is followed by an annealing step happening at 5°C above 
the primer melting temperature for 30 sec for 40 cycles. A final melt curve step was performed at 
95°C for 15 sec, followed by going down to 60°C for 1 minute and a final step at 95°C for 15 sec. 
The control used for qPCR is comprised of 8.75 µl of sterile nuclease free water, 10 µl of Fast 
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SYBR® Green Master Mix and 1.25 µl of gene specific primer at a concentration of 0.5 µM 
(IDTDNA). The reference gene used to test the cDNA quality was Gapdh. Duplicate assay was 
performed for each cell line and reactions were repeated three times for reproducibility purposes.  
Raw threshold (Ct) values were calculated by taking the average after the amplification for 
each of the cell lines. The amplified target genes in each hepatoma and fibroblast cells were 
normalized to Gapdh for the respective Ct‐value, generating a delta-Ct value (ΔCt). Fold 
differences in gene expression were determined with a delta delta‐Ct (ΔΔCt) calculation. The ΔCt 
of the control cell line (Fg14) was subtracted from the hepatoma variant ΔCt value, generating a 
ΔΔCt value. Using a log base 2 scale, the calculated difference was placed into the ΔΔCt equation: 
2(ΔCt (sample – experimental) − (ΔCt Control). 
2.6. Statistical Analysis 
Statistical significance was determined using student t-test assuming unequal variance. 
Significance value was accepted at p < 0.05 level.  
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Chapter 3 
Results 
We used hepatoma cell line Fg14 as a model to study the role of candidate gene Twist1 in 
the regulation of fibroblasts-specific gene expression. The results can be regarded as an extension 
of past studies from our laboratory which originally identified candidate master regulatory genes 
in a genome-wide screening of gene expression in hepatoma x fibroblast cell hybrids that could 
remodel cell hybrids to become more fibroblastic in nature[46]. Previous studies showed that Snai2 
overexpression in hepatoma cells (Fg14) activated expression of fibroblast specific genes[115]. 
Moreover, Snai2 overexpression resulted in repression of liver specific genes. This thesis 
addresses whether Twist1 has a similar effect as Snai2. More specifically, the objective of this 
work is to determine whether Twist1 overexpression in hepatoma cells (Fg14) can reprogram these 
hepatoma cells to become more fibroblast-like.  To that end, we monitored fibroblast specific and 
hepatoma specific gene expression in response to Twist1 overexpression.    
Expression cassettes containing the mouse Twist1gene in a neo plasmid vector was 
transfected into the Fg14 cells and G418 selection applied.  There was only one pool and three 
total clones. A parallel non-transfected negative control was included which, as expected, resulted 
in no G418 resistant clones.  G418 resistant clones were picked individually or pooled and 
expanded into 100mm cell culture dishes. Following this procedure, RNA was extracted and used 
to generate complimentary DNA (cDNA) that was later used in the qPCR reactions to monitor 
expression of target genes. 
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3.1. Expression Comparison of Fibroblast and Hepatoma-specific Genes  
 We first compared gene expression profiles of key liver-specific and fibroblast -specific 
genes between the RAT1 fibroblasts cells and the Fg14 cells using rat-specific primers. For 
hepatoma cells, we measured expression of genes encoding transcription factors known to be 
important in driving the liver phenotype. These included transactivator genes Hnf4, Hnf1, Hnf6 as 
well as Creg1, a gene recently identified in our laboratory as being important for liver function.  
Results show that of these genes are highly liver-specific, with levels 100-1000 fold higher in the 
hepatoma cells compared to those in the RAT2 fibroblast cell line (Fig. 9).  We next measured 
expression of a panel of fibroblast specific genes known to be important in driving the fibroblast 
phenotype. These included Prrx1, Snai2, C-fos, Shox2, Sppl, Col1a, and Sema3a and the gene of 
interest, Twist1.  As expected, result show that Fg14 cell expression of these genes is 2 to 3 orders 
of magnitude lower than in the RAT1 fibroblasts (Fig 10).  
3.2. Twist1 Overexpression in Fg14-transfected Cells 
As shown above, Twist1 is expressed at levels >100 fold lower than those in the RAT2 
fibroblasts.  We next asked whether the transfected mouse Twist1 gene was expressed in 
transfected Fg14 cells. To do this, mouse-specific primers were used, as the rat primers failed to 
cross-hybridize to the mouse cDNA sequences (results not shown).  Results from RT-qPCR 
analysis show that mouse Twist1 was successfully over-expressed in pooled Fg14 transfectants as 
well as two (clones 4 and 8) of the three individual clones compared to the non-transfected Fg14 
cells (Fig. 11).   A third clone (clone 6) showed no detectable expression of the Twists1 transgene, 
and therefore serves as a negative control for non-specific effects. 
As mentioned above, both the pooled clones well as the two out of the three individual 
clones tested expressed the introduced Twist1 gene at levels >2500 fold higher than the signal in 
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the Fg14 cells (Fig. 11) . It is important to mention that since the used primers are mouse-specific, 
background signals in the rat-derived Fg14 cells could either be due to cross-hybridization to rat 
sequences or spurious hybridizations to other sequences.  
3.3. Twist1 Overexpression – Activation of downstream hepatoma-specific genes 
The next set of experiments were done to address the question of whether Twist1 
overexpression in hepatoma cells (Fg14) could affect expression of downstream hepatoma-specific 
genes. Regulation of downstream genes in distinct cell types depends largely upon transcriptional 
control. It is known that regulation and/or activation of liver specific downstream genes 
necessitates binding of hepatocyte nuclear factors and co-activators to promoter regions. Due to 
the established features of Twist1 and its fibroblast specificity, we asked if it could alter liver-
specific downstream genes (which would suggest reprogramming of these cells). Expression of 10 
different key liver markers was monitored. In each case, expression profiles were compared 
between the non-transfected Fg14 cells and the Twist1-transfected cells (pools and three clones).   
All values obtained from the thermal cycle were controlled for Gapdh expression for each 
cell line tested.  All cells lines showed Gapdh levels with 3 cycles and expression results obtained 
for each gene was normalized to these differences in Gapdh levels.  This assumes that Gapdh levels 
are unaffected by introduction of the transgene and instead reflects technical variation in RNA 
isolation, cDNA production, or assay preparation.  
For some of the hepatoma-specific genes including Hnf1, Creg1, Hnf3, and Serpina1 (see 
Figs 12, 17, 18 and 19, respectively), levels were within 3-fold of the non-transfected Fg14 cells. 
For other genes including Hnf4, Alb, Pck1, Kng1 and Fgb (see Figs. 13, 15, 16, 20 and 21, 
respectively) an unexpected increase in expression was observed in clones compared to the Fg14 
parental line.  For example, both Alb and HNF4 showed 5-15 fold activation in the transfected 
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clones compared to the pooled transfectants. Clone 6 produced the highest levels, despite the fact 
that we were unable to detect expression of the introduced transgene in this clone (see Fig. 11), 
leading us to conclude that the levels detected for these genes were independent of Twist1 
expression.    
Of the 10 genes tested, only Hnf6 showed a possible effect on gene expression due to the 
in introduction of the mouse Twists1. The pooled transfectants showed a 6-fold increase, with  
clones 4 and 8 having a more modest 2-fold increase compared to either non-transfected on non-
expressing  Fg14 cells,  Therefore, little if any effect on liver-specific genes expression was 
observed by overexpression of the mouse Twist1 gene.   
3.4. Effect of Twist1 overexpression on fibroblast-specific gene expression 
In the next section, we tried to answer the question of whether Twist1 overexpression in 
hepatoma cells (Fg14) could affect expression of downstream fibroblast genes. As described above 
fibroblast-specific genes expressed at levels more than 100-fold below those in the Fg14 hepatoma 
cell line (Fig10).  Therefore, Pooled Fg14-Twist1 cells were tested for fibroblast-specific gene 
expression using qPCR. Expression of 7 different key fibroblast markers was monitored, in each 
case, expression profiles were compared between the non-transfected Fg14 cells and the Twist1-
transfected cells (pools and three clones).    
All values obtained from the thermal cycle were controlled for Gapdh expression for each 
cell line tested.  All cells lines showed Gapdh levels with 3 cycles of each other,  results obtained 
for expression of each gene was normalized to these differences in Gapdh levels.  This assumes 
that Gapdh levels are unaffected by introduction of the transgene and instead reflects technical 
variation in RNA isolation, cDNA production, or assay preparation.  
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For some of the fibroblast-specific genes including Snai2, C-fos, Col1a1, and Sema3a (see 
Figs. 23, 24, 27, and 28) expression levels were 20 to 90% lower than that of the non-transfected 
Fg14 cells with an unexpected increase in expression for Sema3a clone 4. Additionally, Snai2 
expression levels in Fg pool is comparable to non-transfected Fg14 cells expression levels. For the 
genes Prrx1, Shox2, and Sppl (see Figs. 22, 25, and 26) expression levels were 20 to 95% lower 
than non-transfected Fg14 cells with no expression for some cases, specifically, Prrx pool, Shox2 
clone 8, Sppl pool and clone 6.  
Of the 7 genes tested, only Prrx1 showed significant expression levels for clone which is 
20 to 90 fold compared to non-transfected Fg14 cells while the pool has expressed levels of half 
the intensity.  
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Figure 9. Comparative expression of key liver-specific genes in hepatoma cells vs fibroblast 
cells. Rat-specific primers were used to monitor expression of known liver-specific genes in the 
Fg14 rat hepatoma cell lines and RAT1 fibroblasts cells. cDNA derived from isolated mRNA 
was monitored by qPCR analysis. The cycle numbers shown are compared to those obtained 
from the RAT1 cells and normalized to Gapdh levels using the ΔΔCT method for each cell line. 
The experiments were repeated at least 3 times, with triplicate reactions sets for each.  
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Figure 10. Comparative expression of key fibroblast genes in hepatoma cells vs fibroblast 
cells. Rat-specific primers were used to monitor expression of known liver-specific genes in the 
Fg14 rat hepatoma cell lines and RAT2 fibroblasts cells. cDNA derived from isolated mRNA 
was monitored by qPCR analysis. The cycle numbers shown are compared to those obtained 
from the Fg14 cells and normalized to Gapdh levels using the ΔΔCT method for each cell line. 
The experiments were repeated at least 3 times, with triplicate reactions sets for each. 
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Figure 11. Twist1 overexpression in transfected Fg14 rat hepatoma cells. Mouse-specific 
primers were used to monitor over-expression of the introduced mouse Twist1 gene in the Fg14 
rat hepatoma cell line. Fg14 cells were stably transfected with a mouse Twist1 expression 
plasmid, and G418-resistant clones pooled or selected individually. Cellular mRNA was isolated, 
converted to cDNA, and monitored by qPCR analysis. The cycle numbers shown are compared 
to those obtained from the Fg14 cells and normalized to Gapdh levels using the ΔΔCT method 
for each cell line. The experiments were repeated at least 3 times, with triplicate reactions set for 
each trial. 
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Figure 12.  mTwist1 does not affect Hnf1a expression in Fg14 cells. Rat-specific Hnf1a 
primers were used to monitor Hnf1a expression in transfected cell using qPCR analysis. The 
cycle numbers shown are compared to those obtained from the Fg14 cells and normalized to 
Gapdh levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 
times, with triplicate reactions set for each trial. 
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Figure 13.  mTwist1 activates expression of Hnf4 in Fg14 cells. Rat-specific Hnf4 primers 
were used to monitor Hnf4 expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were performed in triplicate. 
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Figure 14.  mTwist1 activates expression of Hnf6 in Fg14 cells. Rat-specific Hnf6 primers 
were used to monitor Hnfn6 expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were performed in triplicate. 
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Figure 15.  mTwist1 effects on Alb expression in Fg14 cells. Rat-specific Alb primers were 
used to monitor Alb expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
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Figure 16.  mTwist1 effects on Pck1 expression in Fg14 cells. Rat-specific Pck1 primers were 
used to monitor Pck1 expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
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Figure 17.  mTwist1 effects on Creg1 expression in Fg14 cells. Rat-specific Creg1 primers 
were used to monitor Creg1 expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, 
with triplicate reactions set for each trial. 
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Figure 18.  mTwist1 effects on Hnf3 expression in Fg14 cells. Rat-specific Hnf3 primers were 
used to monitor Hnf3 expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
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Figure 19.  mTwist1 effects on Serpina1 expression in Fg14 cells. Rat-specific Serpina1 
primers were used to monitor Serpina1 expression in transfected cell using qPCR analysis. The 
cycle numbers shown are compared to those obtained from the Fg14 cells and normalized to 
Gapdh levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 
times, with triplicate reactions set for each trial. 
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Figure 20.  mTwist1 effects on Kng1 expression in Fg14 cells. Rat-specific Kng1 primers were 
used to monitor Kng1 expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
 
 46 
 
 
Figure 21.  mTwist1 effects on Fgb1 expression in Fg14 cells. Rat-specific Fgb1 primers were 
used to monitor Fgb1 expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
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Figure 22.  mTwist1 effects on Prrx1 expression in Fg14 cells. Rat-specific Prrx1 primers 
were used to monitor Prrx11 expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, 
with triplicate reactions set for each trial. 
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Figure 23.  mTwist1 effects on Snai2 expression in Fg14 cells. Rat-specific Snai2 primers 
were used to monitor Snai2 expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, 
with triplicate reactions set for each trial. 
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Figure 24.  mTwist1 effects on C-fos expression in Fg14 cells. Rat-specific C-fos primers were 
used to monitor C-fos expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
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Figure 25.  mTwist1 effects on Shox2 expression in Fg14 cells. Rat-specific Shox2 primers 
were used to monitor Shox2 expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, 
with triplicate reactions set for each trial. 
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Figure 26.  mTwist1 effects on Spp1 expression in Fg14 cells. Rat-specific Spp1 primers were 
used to monitor Spp1 expression in transfected cell using qPCR analysis. The cycle numbers 
shown are compared to those obtained from the Fg14 cells and normalized to Gapdh levels using 
the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, with 
triplicate reactions set for each trial. 
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Figure 27.  mTwist1 effects on Cola1a expression in Fg14 cells. Rat-specific Cola1a primers 
were used to monitor Cola1a expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, 
with triplicate reactions set for each trial. 
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Figure 28.  mTwist1 effects on Sema3a expression in Fg14 cells. Rat-specific Sema3a primers 
were used to monitor Sema3a expression in transfected cell using qPCR analysis. The cycle 
numbers shown are compared to those obtained from the Fg14 cells and normalized to Gapdh 
levels using the ΔΔCT method for each cell line. The experiments were repeated at least 3 times, 
with triplicate reactions set for each trial. 
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Chapter 4 
Discussion and Future Directions 
Transcription factors (TFs) have a very important role in activation of genes within a 
genome to regulate development in mammalian cells. As described in the literature many control 
mechanisms, namely histone modification, chromatin regulation, transcriptional control, post-
transcriptional regulation and cell-cell contact, regulate gene expression in fibroblast cells[116]. 
Promoter-proximal elements and enhancers initiate transcriptional activity where transcription 
factors bind[117]. Fibroblast-lineage TFs bind to regulatory regions of certain genes in a 
synergistic fashion that leads to activation of these genes to form fibroblast identity in all distinct 
tissues in complex organisms. 
Fibroblast-specific gene expression was studied in our laboratory using cell hybrids as 
model system combined with whole genome microarrays. The genes were identified by comparing 
whole genome transcriptome microarray data of hepatoma cells and hepatoma x fibroblast hybrid 
cells along with parental fibroblast cells by observing the fold differences in expression. The 
experiments identified potential master regulators of fibroblast cell fate (fibroblast-specific TFs), 
and their putative regulatory role in fibroblast differentiation. Among the identified genes are 
transcription factors (e.g. Prrx1/Pmx, Slug, Snai2, Shox2, CFOS, Twistl, Hox-d10, and Msxl) as 
well as fibroblast-specific downstream such as Sema3a, (cell signaling) Sppl, Bmp3 (cell 
differentiation), and Collal (structural organization). 
Among the fibroblast-specific candidate genes identified that have putative roles in the 
maintenance of the fibroblast phenotype were transcription factors Snai2 and Twist1. A previous 
study from our laboratory found out Snai2 was highly expressed in fibroblasts, silent in hepatoma 
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cells, and repressed in hepatoma x fibroblasts cell hybrids. Moreover, forced over-expression of 
these genes in the hybrid cells leads to activation of fibroblast gene expression and resulting 
fibroblast-like morphology. We asked the question of whether a similar effect could be observed 
for Twist1. The goal of this study was to determine the ability of a fibroblast-lineage specific TF 
to remodel hepatoma cells. 
4.1. Reprogramming the gene expression profile of hepatoma cells by Twist1 overexpression 
 In this study, we extended the results of a previous study from our lab which suggested that 
overexpression of Prrx1 and Snai2 genes via introduction of an expression plasmids into the Fg14 
hepatoma cells results in activation of fibroblast-specific TFs as well as downstream fibroblasts-
specific genes. We wanted to determine whether a similar effect can be observed for Twist1 gene. 
We were not able to observe significant activation of key fibroblast-specific TFs. Although not 
studied in here, we speculate that overexpression of Twist1 in the hepatoma cell line might activate 
other fibroblast-specific TFs that work in collaboration with other TFs to define the drive lineage- 
specific transcriptional regulatory circuitry. 
We started with showing that the Twist1 gene is expressed at levels which are 1000-fold 
higher than those in the hepatoma cells (Figure 9). We were able achieve high level expression in 
mouse Twist1 in the rat hepatoma cells using expression vectors from Origene. The results showed 
strong expression of mouse Twist1 gene in the cells compared to non-transfected cells, both in the 
pooled transfectants and some of the individual clones analyzed (Figure 11). 
Over-expression of the mouse Twistl gene in the hepatoma cell line resulted in activation 
of only one fibroblast-specific TFs and two fibroblast-specific downstream genes- Prrx1 and 
Sema3a, respectively (Figures 22 and 28) while the other genes, including C-Fos, Shox2, Snai2, 
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Sppl and Col1a1 (Figures 23, 24, 25, 26, 27) did not show significant activation in both the pool 
and clones. 
Several TFs have been reported as master regulators of the epithelial–mesenchymal 
transition (EMT) program. These include Twist1, Snail family zinc finger 1 (SNAIL1), Zinc finger 
E-box-binding homeobox (ZEB), PRRX1, KLF4, SOX4, and SOX9[118]. Thus, it makes sense to 
assume correlation between Snai2, Prrx1, and Twist in the pathways of EMT. The Col1a1 gene, 
which is a common marker for fibroblast identity, was not activated by Twist1. A similar 
observation took place for Snai2-transfected cells per previous results from our lab, although 
Prrx1-transfected cells showed significant activation. 
Prrx1 is expressed in mesenchymal tissues in adult mice and studies showed that Prrx1 has 
the capability of differentiating mesenchymal precursors. More specifically, Prrx1 was showed to 
inhibit adipogenesis by activating TGF-beta signaling[119]. On another note, Twist 1 was also 
showed to be a regulator of adipocyte gene expression although not likely to regulate 
differentiation[120]. This positive correlation might explain Prrx1 upregulation by overexpression 
of Twist1 gene in hepatoma cell line. 
We observed a high activation level in some of the clones for Sema3a gene (Figure 28) 
which is a member of the semaphorin family and it is secreted by neurons and surrounding tissue 
which guides migrating cells and exons in developing systems. It also serves as an endogenous 
inhibitor of angiogenesis[121]. A similar condition occurs for Twist 1 gene. Studies showed that 
Twist1 is required for Tie2 expression and angiogenesis[122]. This might be a reason why Sema3a 
is upregulated by overexpression of Twist1 gene in hepatoma cell line. 
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4.2. Twist1 in Diseases 
A very important role Twist1 plays besides the role in organogenesis is the expression of 
aggressive tumors in a variety of cancer types such as breast cancer[65], hepatocellular 
carcinoma[88], prostate cancer[89], gastric cancer[90], oesophageal squamous cell carcinoma[91], 
bladder cancer[92] and pancreatic cancer[93]. Twist1 has a presence in cancer initiation, 
progression as well as metastasis[57].  Most well-known effects of Twist1 in cancer is the 
promotion of cancer cell (epithelial-mesenchymal transition) EMT and metastasis. Metastasis has 
many steps including EMT, local invasion, intravasation, transportation, extravasation, 
proliferation at another site and production of overt metastatic lesions[94].  Just as it does for 
development, Twist1 exhibits a similar behavior by supporting the cells to undergo EMT and move 
away to form secondary tumor sites[95].  
Although Twist1 plays an important role for many types of cancers, the way it expresses, 
functions and the molecular mechanisms affected in this process vary for each type of cancer. HCC 
is a metastatic tumor characterized by rapid growth[56]. It has been shown that Twist1 
overexpression has a positive correlation with HCC metastasis and a negative correlation with E-
cadherin expression[88]. The demonstration of higher levels of Twist1 and lower levels of E-
cadherin corresponding to higher metastatic capability implies that Twist1 inhibits E-cadherin 
expression and activates EMT alterations[88]. Upregulation of vascular endothelial growth factor 
(VEGF) and N-cadherin by Twist1 in HCC points to Twist1’s role in HCC angiogenesis[96]. 
Another study demonstrated the increased mobility effect of overexpression of Twist1 on HCC 
cells[97]. In a previous study[98] involving Twist1 and  two other major EMT regulators  (Snail 
and Slug) the synergistic effects of Twist1 and Snail in enhancing HCC metastasis were observed. 
Co-expression of Snail and Twist1 decreased E-cadherin and deteriorated prognosis significantly 
 58 
 
compared to Twist1 expression alone, whereas Slug expression was not significant. Further 
verification comes from a study demonstrating Twist1’s effect on increased motility, invasiveness 
via inhibiting E-cadherin expression and upregulation of N-cadherin[99]. 
On a further note, Twist1 gene mutations in human cause Saethre-Chotzen syndrome which 
is an autosomal dominant inheritance disease[63]. 
4.3. Possible Factors Contributing to Variation in Expression Levels 
Most of the experimental findings exhibit large variation in expression levels and this 
section aims to address possible reasons of why they occur. Firstly, sample acquisition and 
handling before the RNA extraction can contribute to variation because of inappropriate sample 
collection and processing[123]. For example, incubating (37 °C) freshly-obtained mouse liver 
tissue for four hours significantly reduced the measured levels of some mRNAs[124]. Secondly, 
assessment of RNA concentration and purity is determined using a UV/Vis spectrometer. Since at 
260 nm wavelength DNA can be detected in the case of DNA contamination overestimation of 
RNA concentration can occur. The most common way to determine RNA quality is to separate the 
RNA sample in an agarose gel and to visualize using a fluorescent dye[125]. This could have been 
checked before proceeding to qPCR while making sure reagents are still fresh. Another check that 
might have an impact on variability is the presence of more than one DNA fragment. This could 
significantly change the result and including melting curve analysis to make sure a single product 
is amplified[123]. Yet another factor to reduce the variability happens during data normalization. 
We have used GAPDH as reference gene but using multiple genes for normalization has been 
shown to reduce variability[126]. There are a couple of software programs to assess reference gene 
as both GAPDH and ACTB variation for a wide range of tissues has been shown in the 
literature[127]. Yet another reason of variation could be to due technical issues such as qPCR 
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instrument, the detection method, the reaction volume, and the liquid dispensing method. 
Instrument calibration and regular testing are important. Finally, levels of expression for most 
fibroblast genes were close to the detection limit for the RT-qPCR, (> cycle 35) making it likely 
that signals obtained could be suspect. . 
On another note, fibroblast genes were expressed at very low levels in the hepatoma cells 
(often >100 fold lower than in the fibroblasts cells) which possibly explains why the RT-qPCR 
data was highly variable between transfected pools and clones.   
4.4. Future Directions 
 In the experiments, for the Twist1 candidate genes where we observed strong activation 
we are not certain that the cause is Twist1 binding to promoters of the transcription factor 
promoters.  This could be determined by a software that predicts transcription factor binding sites 
(TFBS) paired with functional assays such as ChIP-Chip and ChIP-Seq to detect the binding site 
sequences of Twist1 on promoters. There are several experimental methods to achieve this both in 
vitro and in vivo[128]. In vitro methods include Electro-Mobility Shift Assay (EMSA) which uses 
non-denaturing polyacrylamide gel as a molecular sieve to separate protein-bound DNA from 
unbound DNA, DNase I footprinting/protection assay which combines the cleavage reaction of 
DNase I with EMSA, Systematic Evolution of Ligands by EXponential enrichment (SELEX) that 
works by monitoring short, random oligonucleotide probes that are recognized by a TFBS of 
interest. More recently, in vivo approaches are getting more popular. Chromatin 
ImmunoPrecipitation (ChIP) assay is one such method. 
Moreover, to reduce Twist1 expression in the Fg14 cells gene knockdown experiments can 
be utilized. This experiment would help us find out whether the fibroblast-specific as well as 
downstream genes get affected or not. Furthermore, cell culture models can be established to check 
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Twist1 expression levels during embryogenesis in normal and Twist1 knockout mice model to 
help explain the role of the protein in fibroblast function. Finally, conducting a whole-genome 
microarray analysis on the Fg14-Twist1 cells as opposed to Fg14 cells and Rat cells would pinpoint 
the degree of genomic remodeling as a result of over expression. 
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